24 September 2019
Dechra is pleased to announce a partnership with Vetcare Ltd. (Vetcare) for a patented canine sedative.
This novel combination product provides greater cardiovascular safety as compared to other products of a similar class. The development programme is complete, and with our licensing partner, Vetcare, we expect to launch the new sedative into the first market in 2021, with other territories to follow.
Veterinarians routinely utilize sedatives in their daily practice to ensure the safety and comfort of their patients and the safety of their hospital team. Current canine sedatives carry some concern for cardiac function while the patient is sedated. Vetcare, along with veterinary researchers at the University of Helsinki, has spent many years studying and evaluating a combination of drugs that will help alleviate some of the concern veterinarians and their staff have with the current sedatives available.
Dechra’s Group Director of Business Development and Regulatory Affairs, Dr Susan Longhofer said:
“Dechra is excited to partner with Vetcare on this novel canine sedative which possesses unique cardiovascular advantages over the drugs currently available to veterinary practitioners. This new drug will further enhance Dechra’s leadership position in veterinary anesthesia and analgesia”.
Vetcare’s Chief Executive Officer, Kalevi Heinonen said:
“Vetcare is delighted to partner with Dechra on the commercial launch and long-term sales and marketing of our new canine sedative. This drug launch represents the culmination of almost a decade of work by Vetcare and it will be a strategic product for our business moving forward”.
Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. The majority of Dechra’s products are focused on key therapeutic categories where we have leading market positions, and many of our products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information, please visit: www.dechra.com
About Vetcare, Ltd.
Vetcare is a major Finnish veterinary medicine developer, seller and marketer of veterinary medicines. Vetcare has made Finnish veterinary medicine know-how known worldwide. For more information, please visit: www.vetcare.fi.
Dechra and the Dechra “D” logo are registered trademarks of Dechra Pharmaceuticals PLC.
Dechra and Vetcare Partner for Novel Canine Sedative